The Medical Letter on Drugs and Therapeutics
FROM
ISSUE1735
ISSUE1735
August 18, 2025
Lenacapavir (Yeztugo) for HIV Pre-Exposure Prophylaxis
Subscribers: Log in to read full article. Not a subscriber? Subscribe or purchase article. |
Lenacapavir (Yeztugo) for HIV Pre-Exposure Prophylaxis
August 18, 2025 (Issue: 1735)
The FDA has approved oral and injectable formulations
of the HIV-1 capsid inhibitor lenacapavir (Yeztugo –
Gilead) for pre-exposure prophylaxis (PrEP) to reduce
the risk of sexually acquired HIV-1 in at-risk adolescents
and adults. Lenacapavir...more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.